IL2 and neoplasm: To overcome this issue, IL-2 has been engineered with D20T mutation (IL-2LT) and fused to the C-terminal part of the heavy chain of an NHS76 IgG2 antibody, recognizing DNA structures in the necrotic core of a tumor [105].